scholarly journals Palpation Device for the Identification of Kidney and Bladder Cancer: A Pilot Study

2011 ◽  
Vol 52 (5) ◽  
pp. 768 ◽  
Author(s):  
Jae Won Lee ◽  
Enrique Ian S. Lorenzo ◽  
Bummo Ahn ◽  
Cheol Kyu Oh ◽  
Hyung-Joo Kim ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pilot Study

Abstract 615: Differential pathway analyses of BCG-treated T1HG bladder cancer using Philips OncoSignal: A pilot study

2021 ◽  
Author(s):  
Florus C. De Jong ◽  
Teemu D. Laajala ◽  
Robert F. Hoedemaeker ◽  
Sébastien Rinaldetti ◽  
Jolien T. Mensink ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pilot Study ◽  
Pathway Analyses

Electronic nose to distinguish bladder cancer by urinary odour feature: A pilot study

2020 ◽  
Vol 28 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Kazumasa Matsumoto ◽  
Yasukiyo Murakami ◽  
Yuriko Shimizu ◽  
Takahiro Hirayama ◽  
Wataru Ishikawa ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pilot Study ◽  
Electronic Nose

scholarly journals Application of Health Technology Assessment (HTA) to Evaluate New Laboratory Tests in a Health System: A Case Study of Bladder Cancer Testing

2020 ◽  
Vol 7 ◽  
pp. 237428952096822
Author(s):  
Erik J. Landaas ◽  
Ashley M. Eckel ◽  
Jonathan L. Wright ◽  
Geoffrey S. Baird ◽  
Ryan N. Hansen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pilot Study ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Real World ◽  
Health Technology ◽  
Test System ◽  
Real World Data ◽  
World Data

We describe the methods and decision from a health technology assessment of a new molecular test for bladder cancer (Cxbladder), which was proposed for adoption to our send-out test menu by urology providers. The Cxbladder health technology assessment report contained mixed evidence; predominant concerns were related to the test’s low specificity and high cost. The low specificity indicated a high false-positive rate, which our laboratory formulary committee concluded would result in unnecessary confirmatory testing and follow-up. Our committee voted unanimously to not adopt the test system-wide for use for the initial diagnosis of bladder cancer but supported a pilot study for bladder cancer recurrence surveillance. The pilot study used real-world data from patient management in the scenario in which a patient is evaluated for possible recurrent bladder cancer after a finding of atypical cytopathology in the urine. We evaluated the type and number of follow-up tests conducted including urine cytopathology, imaging studies, repeat cystoscopy evaluation, biopsy, and repeat Cxbladder and their test results. The pilot identified ordering challenges and suggested potential use cases in which the results of Cxbladder affected a change in management. Our health technology assessment provided an objective process to efficiently review test performance and guide new test adoption. Based on our pilot, there were real-world data indicating improved clinician decision-making among select patients who underwent Cxbladder testing.

Combined Cis-Platinum and Radiation Therapy in Patients with Stages PT3 and PT4 Bladder Cancer: A Pilot Study

1983 ◽  
Vol 129 (3) ◽  
pp. 501-504 ◽  
Author(s):  
Gerhard Jakse ◽  
Hermann Frommhold ◽  
Hans Marberger
Keyword(s):  
Bladder Cancer ◽  
Radiation Therapy ◽  
Pilot Study
Sign in / Sign up

Export Citation Format

Share Document